5 Apricus Biosciences Analyst Ratings, Earnings, Dividends and Insider Trades | $APRI | NASDAQ:APRI | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Apricus Biosciences Company Profile (NASDAQ:APRI) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Apricus Biosciences (NASDAQ:APRI) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)Consensus Rating:Buy (Score: 2.50)Consensus Price Target: $3.50 (47.06% upside) Analysts' Ratings History for Apricus Biosciences (NASDAQ:APRI) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare8/23/2013Cantor FitzgeraldInitiated CoverageHold$2.00View 3/19/2013JMP SecuritiesLower Price TargetMarket Outperform$6.00 -> $5.00View 7/27/2012Lazard Ltd.Initiated CoverageBuyView 7/23/2012Ascendiant Capital MarketsInitiated CoverageStrong-Buy$6.00View 6/14/2012JMP SecuritiesInitiated CoverageOutperform$6.00View 6/6/2012Roth CapitalInitiated CoverageBuyView (Data available from 3/7/2012 forward) Earnings History for Apricus Biosciences (NASDAQ:APRI)No earnings announcements for this company have been tracked by Analyst Ratings Network Dividend History for Apricus Biosciences (NASDAQ:APRI)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Apricus Biosciences (NASDAQ:APRI)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View 12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View 6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View 5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View 5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View 5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View 5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View 8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View 8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View (Data available from 1/1/2013 forward) About Apricus Biosciences Apricus Biosciences, Inc., formerly NexMed, Inc., is a pharmaceutical research and development company focused on the design and development of products and technologies in multiple therapeutic areas, including oncology, sexual dysfunction, autoimmune diseases and pain/inflammation. Its drug delivery technology is called NexACT. The Company has two operating segments: designing and developing pharmaceutical products (The NexACT drug delivery technology business) and providing pre-clinical CRO services (The Bio-Quant CRO business). In March 2010, the Company acquired PrevOnco, a marketed anti-ulcer compound, lansoprazole, for the treatment of solid tumors. On December 14, 2009, the Company acquired Bio-Quant, Inc. (Bio-Quant). Headlines: (3/4) Apricus Biosciences to Present at the 26th Annual ROTH Conference (2/10) Apricus and Recordati Sign Exclusive License Agreement to Market Topical Erectile Dysfunction Cream - Vitaros(R) in ... (2/10) RECORDATI : OBTAINS VITAROS(R) LICENSE FROM APRICUS BIOSCIENCES (2/12) Apricus Shares Marginally Down on Vitaros Deal (2/10) DGAP-News: Apricus and Recordati Sign Exclusive License Agreement to Market Topical Erectile Dysfunction Cream ... Industry, Sector and Symbol: Sector: N/A Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: APRI CUSIP: Key Metrics: Previous Close: $2.3750 Day Moving Average: $2.33200 Day Moving Average: $2.1277 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $89.3MCurrent Quarter EPS Consensus Estimate: $-0.49 EPS Additional Links: View APRI on Google FinanceView APRI on Yahoo FinanceView APRI's Company Profile on ReutersSearch for Apricus Biosciences on Google Apricus Biosciences (NASDAQ:APRI) Chart for Friday, March, 7, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.